ITGA4 As a Potential Prognostic and Immunotherapeutic Biomarker in Human Cancer and Its Clinical Significance in Gastric Cancer: an Integrated Analysis and Validation

Overview

Journal Front Oncol

Specialty Oncology

Date 2025 Feb 27

PMID 40012546

Authors

Jiaxing Zhang

Gang Wang

Jie Liu

Futian Tang

Song Wang

Yumin Li

Affiliations

Soon will be listed here.

Abstract

Background: Integrin Subunit Alpha 4 (ITGA4), a member of the integrin protein family, is involved in the progression of malignant tumors. However, its role across different cancer types is not well understood.

Methods: Utilizing multi-omics data, we comprehensively evaluated ITGA4's expression, clinical relevance, diagnostic and prognostic value, functions, mutations, and methylation status, along with its impact on immunity, mismatch repair (MMR), heterogeneity, stemness, immunotherapy responsiveness, and drug resistance in pan-cancer, with partial validation in gastric cancer (GC) using transcriptomic analysis, single-cell data, western blot (WB), wound-healing assay, flow cytometry and immunohistochemistry (IHC). We further investigated its correlation with clinicopathology and serological markers on tissues from 80 GC patients.

Results: ITGA4 expression was generally low in normal tissues but varied significantly across tumor types, with higher levels in advanced stages and grades. It demonstrated diagnostic value in 20 cancer types and effectively predicted 1-, 3-, and 5-year survival rates as part of a prognostic model. ITGA4 played roles in cell adhesion, migration, immune regulation, and pathways like PI3K-Akt and TSC-mTOR. It showed alterations in 22 cancer types, with methylation at 9 sites inhibiting its expression. ITGA4 positively correlated with immune cell infiltration, immune regulatory genes, chemokines, and might reduce microsatellite instability (MSI) and tumor mutation burden (TMB) by promoting MMR gene expression. It could also predict immunotherapy efficacy and chemotherapy sensitivity. In GC, high ITGA4 expression was related to poor prognosis, promoted tumor proliferation and migration, and enhanced immune cell infiltration. ITGA4 expression was higher in GC cells and tissues than normal ones. Its downregulation inhibited GC cell migration and promoted apoptosis. Moreover, ITGA4 was correlated with N stage, pathological stage, neural and vascular invasion, serum levels of Ki-67, immune cells, CRP and CA125.

Conclusion: ITGA4 is a potential biomarker and therapeutic target to enhance cancer treatment and improve patient outcomes.

References

Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z . clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3):100141. PMC: 8454663. DOI: 10.1016/j.xinn.2021.100141. View

Yabo Y, Niclou S, Golebiewska A . Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma. Neuro Oncol. 2021; 24(5):669-682. PMC: 9071273. DOI: 10.1093/neuonc/noab269. View

Wu H, Yu Z, Liu Y, Guo L, Teng L, Guo L . Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract. Cancer Commun (Lond). 2022; 42(12):1367-1386. PMC: 9759768. DOI: 10.1002/cac2.12372. View

Takasaka N, Seed R, Cormier A, Bondesson A, Lou J, Elattma A . Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells. JCI Insight. 2018; 3(20). PMC: 6237456. DOI: 10.1172/jci.insight.122591. View

Schmid M, Avraamides C, Dippold H, Franco I, Foubert P, Ellies L . Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 2011; 19(6):715-27. PMC: 3144144. DOI: 10.1016/j.ccr.2011.04.016. View

Strelnikov V, Kuznetsova E, Tanas A, Rudenko V, Kalinkin A, Poddubskaya E . Abnormal promoter DNA hypermethylation of the integrin, nidogen, and dystroglycan genes in breast cancer. Sci Rep. 2021; 11(1):2264. PMC: 7838398. DOI: 10.1038/s41598-021-81851-y. View

Schlesinger M, Bendas G . Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis. Cancer Metastasis Rev. 2015; 34(4):575-91. DOI: 10.1007/s10555-014-9545-x. View

Hight-Warburton W, Parsons M . Regulation of cell migration by α4 and α9 integrins. Biochem J. 2019; 476(4):705-718. DOI: 10.1042/BCJ20180415. View

Foubert P, Kaneda M, Varner J . PI3Kγ Activates Integrin α and Promotes Immune Suppressive Myeloid Cell Polarization during Tumor Progression. Cancer Immunol Res. 2017; 5(11):957-968. PMC: 6422969. DOI: 10.1158/2326-6066.CIR-17-0143. View

10.

Liu C, Hu F, Xie G, Miao Y, Li X, Zeng Y . GSCA: an integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. Brief Bioinform. 2022; 24(1). DOI: 10.1093/bib/bbac558. View

11.

Liu F, Wu Q, Dong Z, Liu K . Integrins in cancer: Emerging mechanisms and therapeutic opportunities. Pharmacol Ther. 2023; 247:108458. DOI: 10.1016/j.pharmthera.2023.108458. View

12.

Xie J, Yang P, Lin H, Li Y, Clementino M, Fenske W . Integrin α4 up-regulation activates the hedgehog pathway to promote arsenic and benzo[α]pyrene co-exposure-induced cancer stem cell-like property and tumorigenesis. Cancer Lett. 2020; 493:143-155. PMC: 9083130. DOI: 10.1016/j.canlet.2020.08.015. View

13.

Tsoumakidou M . The advent of immune stimulating CAFs in cancer. Nat Rev Cancer. 2023; 23(4):258-269. DOI: 10.1038/s41568-023-00549-7. View

14.

Mikeska T, Bock C, Do H, Dobrovic A . DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev Mol Diagn. 2012; 12(5):473-87. DOI: 10.1586/erm.12.45. View

15.

Dai X, Ren T, Zhang Y, Nan N . Methylation multiplicity and its clinical values in cancer. Expert Rev Mol Med. 2021; 23:e2. PMC: 8086398. DOI: 10.1017/erm.2021.4. View

16.

Arana M, Kunkel T . Mutator phenotypes due to DNA replication infidelity. Semin Cancer Biol. 2010; 20(5):304-11. PMC: 3087159. DOI: 10.1016/j.semcancer.2010.10.003. View

17.

Han Y, Wang Y, Dong X, Sun D, Liu Z, Yue J . TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. Nucleic Acids Res. 2022; 51(D1):D1425-D1431. PMC: 9825603. DOI: 10.1093/nar/gkac959. View

18.

Baumann T, Delgado J, Santacruz R, Martinez-Trillos A, Rozman M, Aymerich M . CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status. Br J Haematol. 2015; 172(1):48-55. DOI: 10.1111/bjh.13788. View

19.

Li M, Ye J, Xia Y, Li M, Li G, Hu X . METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4. Leukemia. 2022; 36(11):2586-2595. PMC: 9613467. DOI: 10.1038/s41375-022-01696-w. View

20.

Byrne S, Boyle T, Ahmed M, Lee S, Benyamin B, Hypponen E . Lifestyle, genetic risk and incidence of cancer: a prospective cohort study of 13 cancer types. Int J Epidemiol. 2023; 52(3):817-826. PMC: 10244040. DOI: 10.1093/ije/dyac238. View